Neurocrine Biosciences

This study tests whether valbenazine can help people with tardive dyskinesia (uncontrollable movements) who still have symptoms while taking or after stopping another drug. About 50 adults with schizophrenia, bipolar disorder, or major depression will take valbenazine for 24 week…

This study is testing an experimental drug called crinecerfont in 6 infants under 2 years old who have congenital adrenal hyperplasia (CAH), a condition where the body can't make certain hormones properly. The goal is to see how the drug moves through the body and if it is safe. …

This study tests whether adding the experimental drug NBI-1065845 to standard antidepressants can delay the return of depression symptoms in adults with major depressive disorder. About 550 participants who have not fully responded to current antidepressants will receive either t…

This study checks the long-term safety of an experimental drug called NBI-1117568 in 600 adults with schizophrenia. Participants must stop taking other antipsychotic medications before joining. The main goal is to track any side effects that occur during treatment.

This study tests an experimental drug called NBI-1117568 to see if it can improve schizophrenia symptoms better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a dummy pill for 5 weeks. The main goal is to measure changes in sympto…

This study tests an experimental drug called NBI-1117568 to see if it can improve schizophrenia symptoms like hallucinations and confusion in adults who need hospital care. About 284 participants will receive either the drug or a placebo for 5 weeks while staying in the hospital.…

This study tests whether adding NBI-1065845 to standard antidepressants can better reduce depression symptoms in adults with major depressive disorder who haven't improved enough with current medication. About 200 participants will receive either the study drug or a placebo for 8…

This study tests an experimental drug, NBI-1117568, to see if it can reduce manic symptoms in adults with bipolar I disorder who are hospitalized for a manic episode. About 150 participants will receive either the drug or a placebo for 21 days. The main goal is to measure changes…

This study tests the long-term safety of an experimental drug called NBI-1065845 when added to standard antidepressants for people with major depression. About 850 adults who haven't gotten enough relief from current treatments will take the drug for up to a year. The main goal i…

This study tests whether a new drug called NBI-1065845 can improve depression symptoms in adults who still feel depressed despite taking standard antidepressants. About 200 participants will receive either the study drug or a placebo pill alongside their usual medication for 8 we…